Functional Brain Dysconnectivity in Parkinson's Disease: A 5‐Year Longitudinal Study

Movement Disorders, Journal Year: 2022, Volume and Issue: 37(7), P. 1444 - 1453

Published: April 14, 2022

Abstract Background Tracking longitudinal functional brain dysconnectivity in Parkinson's disease (PD) is a key element to decoding the underlying physiopathology and understanding PD progression. Objectives The objectives of this follow‐up study were explore, for first time, changes networks patients over 5 years associate them with their cognitive performance lateralization motor symptoms. Methods We used 5‐year cohort (n = 35) who completed non‐motor assessments sequent resting state (RS) high‐density electroencephalography (HD‐EEG) recordings at three timepoints: baseline (BL), 3 (3YFU) (5YFU). assessed disruptions frequency‐dependent course explored relation clinical symptomatology. Results In contrast HC 32), showed gradual connectivity impairment α2 (10‐13 Hz) β (13–30 frequency bands. deterioration global assessment was strongly correlated disconnected networks. These also associated symptoms, revealing dominance right hemisphere terms impaired connections left‐affected left right‐affected patients. Conclusions Taken together, our findings suggest that progression, can reflect deficits RS HD‐EEG may be an early biomarker © 2022 Authors. Movement Disorders published by Wiley Periodicals LLC on behalf International Parkinson Disorder Society

Language: Английский

---

Clinical Parkinson disease subtyping does not predict pathology

Nature Reviews Neurology, Journal Year: 2019, Volume and Issue: 15(4), P. 189 - 190

Published: Feb. 20, 2019

Language: Английский

---

Seven Solutions for Neuroprotection in Parkinson's Disease

Movement Disorders, Journal Year: 2020, Volume and Issue: 36(2), P. 306 - 316

Published: Nov. 13, 2020

ABSTRACT Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation iron alpha‐synuclein; it follows characteristic pattern throughout nervous system. Despite decades successful preclinical neuroprotective studies, no drug has then shown efficacy clinical trials. Considering this dilemma, we have reviewed organized solutions varying importance that can be exclusive or additive, outline approaches to help generate development drugs for PD: (1) select patients which targeted mechanism involved pathological process associated with monitoring target engagement, (2) combine treatments multiple pathways, (3) establish earliest interventions develop better prodromal biomarkers, (4) adopt rigorous methodology specific disease‐relevant designs disease‐modifying trials, (5) customize brain biodistribution, (6) prioritize repurposed as first line approach, (7) adapt models mechanisms translational biomarkers increase their predictive value. © 2020 International Parkinson Movement Disorder Society

Language: Английский

---

Robust identification of Parkinson's disease subtypes using radiomics and hybrid machine learning

Computers in Biology and Medicine, Journal Year: 2020, Volume and Issue: 129, P. 104142 - 104142

Published: Nov. 26, 2020

Language: Английский

---

Feature selection and machine learning methods for optimal identification and prediction of subtypes in Parkinson's disease

Computer Methods and Programs in Biomedicine, Journal Year: 2021, Volume and Issue: 206, P. 106131 - 106131

Published: April 29, 2021

Language: Английский

---

Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(21)

Published: Jan. 25, 2024

Parkinson's disease (PD) is one of the most devastating neurological diseases; however, there no effective cure yet. The availability human induced pluripotent stem cells (iPSCs) provides unprecedented opportunities to understand pathogenic mechanism and identification new therapy for PD. Here a model system PD, including 2D iPSC-derived midbrain dopaminergic (mDA) neurons, 3D organoids (MOs) with cellular complexity, more advanced microphysiological systems (MPS) organoids, introduced. It believed that successful integrations applications iPSC, organoid, MPS technologies can bring insight on PD's pathogenesis will lead treatments this debilitating disease.

Language: Английский

---

Refining the clinical diagnosis of Parkinson's disease

Parkinsonism & Related Disorders, Journal Year: 2024, Volume and Issue: 122, P. 106041 - 106041

Published: Feb. 10, 2024

Language: Английский

---

Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications

Journal of Neurology, Journal Year: 2020, Volume and Issue: 267(10), P. 2949 - 2960

Published: June 2, 2020

Language: Английский

---

The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

Movement Disorders, Journal Year: 2021, Volume and Issue: 36(3), P. 594 - 598

Published: March 1, 2021

Language: Английский

---

A Systematic Review of Parkinson’s Disease Cluster Analysis Research

Aging and Disease, Journal Year: 2021, Volume and Issue: 12(7), P. 1567 - 1567

Published: Jan. 1, 2021

One way to understand the Parkinson's disease (PD) population is investigate similarities and differences among patients through cluster analysis, which may lead defined, patient subgroups for diagnosis, progression tracking treatment planning. This paper provides a systematic review of PD clustering research, evaluating variables included in clustering, methods applied, resulting subgroups, evaluation metrics. A search was conducted from 1999 2021 on PubMed database, using various terms including: disease, cluster, analysis. The majority studies variety clinical scale scores many provide numerical, but ordinal, categorical value. Even though are these were treated as numerical values with continuous being focus limited attention variables, such gender family history, also useful insights into progression, treatment. results pointed two five clusters, age onset duration. lacked use existing metrics points need thorough, analysis framework, consensus appropriate include Accurate assist determining if patients' symptoms can be based subgroup features, personalized care required, or mix individualized group-based best approach.

Language: Английский

---